Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

Lammers, Twan; Hennink, Wim E.; Storm, Gerrit

doi:10.1016/j.jconrel.2011.09.063

Cited by 1,166 publications

(787 citation statements)

References 97 publications

Supporting

Mentioning

778

Contrasting

Unclassified

Order By: Relevance

“…In spite of the development in diagnostic and therapeutic methods, the outcome after treatment remains poor mainly because of the potential of tumor cells to invade and metastasize (Rasheed et al, 2010;Deng et al, 2014;Huang et al, 2014). Targeted therapies are commonly used in combination with traditional chemotherapy currently (Liloglou et al, 2014), and targeted drugs are more effective and have less severe side effects than standard chemotherapy drugs (Lammers et al, 2012). Under these circumstances, discovery of novel and effective biomarkers for lung cancer diagnosis and prognosis as well as new therapeutic targets becomes imperative.…”

Section: Introductionmentioning

confidence: 99%

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Liu

Wu²,

Guo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: Lung cancer is one of the malignant tumors with greatest morbidity and mortality around the world. The keys to targeted therapy are discovery of lung cancer biomarkers to facilitate improvement of survival and quality of life for the patients with lung cancer. Translationally controlled tumor protein (TCTP) is one of the most overexpressed proteins in human lung cancer cells by comparison to the normal cells, suggesting that it might be a good biomarker for lung cancer. Materials and Methods: In the present study, the targeted efficacy of dihydroartemisinin (DHA) on TCTP expression in the A549 lung cancer cell model was explored. Results and Conclusions: DHA could inhibit A549 lung cancer cell proliferation, and simultaneously up-regulate the expression of TCTP mRNA, but down-regulate its protein expression in A549 cells. In addition, it promoted TCTP protein secretion. Therefore, TCTP might be used as a potential biomarker and therapeutic target for non-small cell lung cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Liu

Wu²,

Guo³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Ideally, nanomedicines should circulate, extravasate (in case of IV injection), accumulate and finally penetrate into the tumor. Unlike for IV administration, where tens of studies investigated the biodistribution and ability of different nanomedicines to accumulate at tumor sites [58,59], only (very) limited data are available on the biodistribution of NPs following IP injection (table 1). The biodistribution of non-PEGylated (450 nm in size) and PEGylated (30-100 nm in size) graphene oxide NPs was assessed in healthy animals following IP administration [60].…”

Section: Biodistribution Of Nps Following Ip Injectionmentioning

confidence: 99%

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Dakwar

Shariati

Willaert

et al. 2017

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the academia and clinic in developing IP therapeutic approaches that maximize local efficacy while limiting systemic side effects. Also nanomedicines are under investigation for the treatment of tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the IP cavity yet. This review discusses the current clinical management of PC, as well as recent advances in nanomedicines-based IP delivery.We address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.

show abstract

“…For example, subcutaneously injected tumor in rodents can grow up to ±1 cm within few weeks, if this is related to the human tumors, it represents ±20 cm tumor growth. [8] As the tumor growth is more rapid in murine tumor models, blood vessels are not developed properly, instead are highly vascularized and leaky, simple stromal structure with low density, whereas in humans all tumor vessels are not necessarily leaky, highly dense stroma, which leads to heterogeneous distribution. Nevertheless, although preclinical studies from murine tumor models are consistent, yet insufficient to correlate the clinical outcome in human patients.…”

Section: Epr In Humansmentioning

confidence: 99%

“…[2][3][4][5][6][7] The application of nanotechnology in cancer therapy, herein referred as cancer nanomedicines, have received wide spread attention due to the unique physicochemical properties of the nanoparticles with the ability to deliver different therapeutics (e.g., chemotherapeutics and biologics), altering their pharmacokinetic profiles, augmenting their accumulation in the tumors and reducing their toxicity profiles. [8][9][10][11] Nanomedicines aim to improve the balance between therapeutic efficacy and systemic toxicity of conventional chemotherapeutic agents, which lack of specificity, thereby enhancing the therapeutic index of the anticancer drugs. In clinical cancer care more evidences have been suggested that nanoparticles found to be localized in solid tumors after the systemic (intravenous) administration of nanomedicines to cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress

Cited by 1,166 publications

References 97 publications

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Contact Info

Product

Resources

About